1. Name Of The Medicinal Product
Azocan 200mg Capsules.
Fluconazole 200mg Capsules
2. Qualitative And Quantitative Composition
Each capsule contains Fluconazole 200mg.
For excipients, see 6.1.
3. Pharmaceutical Form
Hard capsule.
A hard gelatin size “0” capsule with a violet cap and white body containing a white free flowing powder.
4. Clinical Particulars
4.1 Therapeutic Indications
Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.
Fluconazole is indicated for the treatment of the following conditions:
1. Genital candidiasis. Vaginal candidiasis, acute or recurrent. Candidal balanitis. The treatment of partners who present with symptomatic genital candidiasis should be considered.
2. Mucosal candidiasis. These include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). Normal hosts and patients with compromised immune function may be treated.
3. Tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal Candida infections. Fluconazole is not indicated for nail infections.
4. Systemic candidiasis including candidaemia, disseminated candidiasis and other forms of invasive candidal infection. These include infections of the peritoneum, endocardium and pulmonary and urinary tracts. Candi infections in patients with malignancy, in intensive care units or those receiving cytotoxic or immunosuppressive therapy may be treated.
5. Cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). Normal hosts, and patients with AIDS, organ transplants or other causes of immunosuppression may be treated. Fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with AIDS.
6. For the prevention of fungal infections in immunocompromised patients considered at risk as a consequence of neutropenia following cytotoxic chemotherapy or radiotherapy, including bone marrow transplant patients
4.2 Posology And Method Of Administration
For oral use.
The daily dose of fluconazole should be based on the nature and severity of the fungal infection. Most cases of vaginal candidiasis respond to single dose therapy. Therapy for those types of infections requiring multiple dose treatment should be continued until clinical parameters or laboratory tests indicate that active fungal infection has subsided. An inadequate period of treatment may lead to recurrence of active infection. Patients with AIDS and cryptococcal meningitis usually require maintenance therapy to prevent relapse.
In Adults:
1) Candidal vaginitis or balanitis: 150mg single oral dose.
2) Mucosal candidiasis
a) Oropharyngeal candidiasis: The usual dose is 50mg once daily for 7–14 days. Treatment should not normally exceed 14 days except in severely immunocompromised patients.
b) For atrophic oral candidiasis associated with dentures: The usual dose is 50mg once daily for 14 days administered concurrently with local antiseptic measures to the denture.
c) For other candidal infections of mucosa except genital candidiasis (see above), e.g. oesophagitis, non-invasive bronchopulmonary infections, candiduria, mucocutaneous candidiasis etc., the usual effective dose is 50mg daily, given for 14 – 30 days.
In unusually difficult cases of mucosal candidal infections the dose may be increased to 100mg daily.
3) For tinea pedis, corporis, cruris, versicolor, and dermal Candida infections: The recommended dose is 50mg once daily. Duration of treatment is normally 2 to 4 weeks but tinea pedis may require treatment for up to 6 weeks. Duration of treatment should not exceed 6 weeks
4) For candidaemia, disseminated candidiasis and other invasive candidal infections: The usual dose is 400mg on the first day followed by 200mg daily. Depending on the clinical response the dose may be increased to 400mg daily. Duration of treatment is based upon the clinical response.
5) For cryptococcal meningitis and cryptococcal infections at other sites: The usual dose is 400mg on the first day followed by 200mg – 400mg once daily. Duration of treatment for cryptococcal infections will depend on the clinical and mycological response, but is usually at least 6 - 8 weeks for cryptococcal meningitis.
6) For the prevention of relapse of cryptococcal meningitis in patients with AIDS, after the patient receives a full course of primary therapy: Fluconazole may be administered indefinitely at a daily dose of 100 – 200mg.
7) For the prevention of fungal infections in immunocompromised patients considered at risk as a consequence of neutropenia following cytotoxic chemotherapy or radiotherapy: The dose should be 50 – 400mg once daily, based on the patient's risk for devoping fungal infection. For patients at high risk of systemic infection, e.g. patients who are anticipated to have profound or prolonged neutropenia such as during bone marrow transplantation, the recommended dose is 400mg once daily. Fluconazole administration should start several days before the anticipated onset of neutropenia, and continue for 7 days after the neutrophil count rises above 1000 cells per mm3.
In Children:
As with similar infections in adults, the duration of treatment is based on the clinical and mycological response. Fluconazole is administered as a single daily dose each day.
For children with impaired renal function, see dosing in “Use in patients with impaired renal function”.
Children over 4 weeks of age (and where a capsule preparation is suitable):
1) For Mucosal candidiasis: The recommended dose of fluconazole is 3mg/kg body weight daily. A loading dose of 6mg/kg body weight may be used on the first day to achieve steady state levels more rapidly.
2) For Systemic candidiasis and cryptococcal infections: The recommended dose is 6-12mg/kg body weight daily, depending on the severity of the disease.
3) For prevention of fungal infections in immunocompromised patients considered at risk as a consequence of neutropenia following cytotoxic chemotherapy or radiotherapy: The dose should be 3 – 12mg/kg body weight daily, depending on the extent and duration of the induced neutropenia (see adult dosing).
A maximum dosage of 400mg daily should not be exceeded in children.
Despite extensive data supporting the use of fluconazole in children there are limited data available on the use of fluconazole for genital candidiasis in children below 16 years of age. Use at present is not recommended unless antifungal treatment is imperative and no suitable alternative agent exists.
Children below 4 weeks of age:
(Capsule form is not suitable for this age group)
Neonates excrete fluconazole slowly. In the first two weeks of life the same mg/kg dosing as in older children should be used but administered every 72 hours. During weeks 2 – 4 of life the same dose should be given every 48 hours.
A maximum dosage of 12 mg/kg every 72 hours should not be exceeded in children below two weeks of life. For children between 2 – 4 weeks of life 12 mg/kg every 48 hours should not be exceeded.
For children with impaired renal function the daily dose should be reduced in accordance with the guidelines given for adults.
To facilitate accurate measurement of doses less than 10mg, fluconazole should only be administered to children in hospital using preparations available in oral suspension or intravenous infusion.
In the Elderly:
The normal adult dose should be used if there is no evidence of renal impairment. In patients with renal impairment (creatinine clearance less than 50ml/min) the dosage schedule should be adjusted as described below.
Use in patients with impaired renal function:
Fluconazole is excreted predominantly in the urine as unchanged drug. No adjustments in single dose therapy are required. In patients (including children) with impaired renal function who will receive multiple doses of fluconazole, the normal recommended dose (according to indication) should be given on day 1, followed by a daily dose based on the following table:
Creatinine clearance (ml/min)
|
Percent of recommended dose
|
> 50
|
100%
|
|
50%
|
Regular dialysis
|
100% after each dialysis
|
4.3 Contraindications
Fluconazole should not be used in patients with known hypersensitivity to fluconazole or to related azole compounds or to any of the other ingredients.
Co-administration of terfenadine or cisapride is contraindicated in patients receiving fluconazole. (See “Interactions with other medicinal products and other forms of interaction”).
4.4 Special Warnings And Precautions For Use
Patients with rare hereditary problems of galactose intolerance, the LAPP lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Use with caution in patients with renal impairment. (See “Use in patients with impaired renal function” in Section 4.2).
In some patients, particularly those with serious underlying diseases such as AIDS and cancer, abnormalities in haematological, hepatic, renal and other biochemical function test results have been observed during treatment with fluconazole but the clinical significance and relationship to treatment is uncertain.
Very rarely, patients who died with severe underlying disease and who had received multiple doses of fluconazole had post-mortem findings which included hepatic necrosis. These patients were receiving multiple concomitant medications, some known to be potentially hepatotoxic, and/or had underlying diseases which could have caused the hepatic necrosis.
In cases of hepatotoxicity, no obvious relationship to total daily dose of fluconazole, duration of therapy, sex or age of the patient has been observed; the abnormalities have usually been reversible on discontinuation of fluconazole therapy.
As a causal relationship with fluconazole cannot be excluded, patients who develop abnormal liver function tests during fluconazole therapy should be monitored for the development of more serious hepatic injury. Fluconazole should be discontinued if clinical signs or symptoms consistent with liver disease develop during treatment with fluconazole.
Patients have rarely developed exfoliative cutaneous reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis, during treatment with fluconazole. AIDS patients are more prone to the development of severe cutaneous reactions to many drugs. If a rash develops in a patient treated for a superficial fungal infection which is considered attributable to fluconazole, further therapy with this agent should be discontinued. If patients with invasive/systemic fungal infections develop rashes, they should be monitored closely and fluconazole discontinued if bullous lesions or erythema multiforme develop.
In rare cases, as with other azoles, anaphylaxis has been reported.
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
Rifampicin
Concomitant administration of fluconazole and rifampicin resulted in a 25% decrease in the AUC and 20% shorter half-life of fluconazole. In patients receiving concomitant rifampicin, an increase in the fluconazole dose should be considered.
Hydrochlorothiazide
In a kinetic interaction study, co-administration of multiple-dose hydrochlorothiazide to healthy volunteers receiving fluconazole increased plasma concentrations of fluconazole by 40%. An effect of this magnitude should not necessitate a change in the fluconazole dose regimen in subjects receiving concomitant diuretics, although the prescriber should bear it in mind.
Anticoagulants
In an interaction study, fluconazole increased the prothrombin time (12%) after warfarin administration in healthy males. As with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, haematuria and melaena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. Prothrombin time in patients receiving coumarin-type anticoagulants should be carefully monitored.
Benzodiazepines (Short acting)
Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. If concomitant benzodiazepine therapy is necessary in patients being treated with fluconazole, consideration should be given to decreasing the benzodiazepine dosage and the patients should be appropriately monitored.
Sulphonylureas
Fluconazole has been shown to prolong the serum half-life of concomitantly administered oral sulphonylureas (chlorpropamide, glibenclamide, glipizide and tolbutamide) in healthy volunteers. Fluconazole and oral sulphonylureas may be co-administered to diabetic patients, but the possibility of a hypoglycaemic episode should be borne in mind.
Phenytoin
Concomitant administration of fluconazole and phenytoin may increase the levels of phenytoin to a clinically significant degree. If it is necessary to administer both drugs concomitantly, phenytoin levels should be monitored and the phenytoin dose adjusted to maintain therapeutic levels.
Oral contraceptives
Two kinetic studies with combined oral contraceptives have been performed using multiple doses of fluconazole. There were no relevant effects on either hormone level in a 50mg fluconazole study, while at 200mg daily the AUCs of ethinyloestradiol and levonorgestrel were increased 40% and 24% respectively. Thus multiple dose use of fluconazole at these doses is unlikely to have an effect on the efficacy of the combined oral contraceptive.
Endogenous steroid
Fluconazole 50mg daily does not affect endogenous steroid levels in females: 200 – 400mg daily has no clinically significant effect on endogenous steroid levels or on ACTH stimulated response in healthy male volunteers.
Ciclosporin
A kinetic study in renal transplant patients found fluconazole 200mg daily to slowly increase ciclosporin concentrations. However, in another multiple dose study with 100mg daily, fluconazole did not affect ciclosporin levels in patients with bone marrow transplants. Ciclosporin plasma concentration monitoring in patients receiving fluconazole is recommended.
Theophylline
In a placebo controlled interaction study, the administration of fluconazole 200mg for 14 days resulted in an 18% decrease in the mean plasma clearance of theophylline. Patients who are receiving high doses of theophylline or who are otherwise at increased risk for theophylline toxicity should be observed for signs of theophylline toxicity while receiving fluconazole, and the therapy modified appropriately if signs of toxicity develop.
Terfenadine
Because of the occurrence of serious dysrhythmias secondary to prolongation of the QTc interval in patients receiving other azole antifungals in conjunction with terfenadine, interactions studies have been performed. One study at a 200mg daily dose of fluconazole failed to demonstrate a prolongation in QTc interval. Another study at a 400mg and 800mg daily dose of fluconazole demonstrated that fluconazole taken in multiple doses of 400mg per day or greater significantly increased plasma levels of terfenadine when taken concomitantly. There have been spontaneously reported cases of palpitations, tachycardia, dizziness, and chest pain in patients taking concomitant fluconazole and terfenadine where the relationship of the reported adverse events to drug therapy or underlying medical conditions was not clear. Because of the potential seriousness of such an interaction, it is recommended that terfenadine not be taken in combination with fluconazole. (See “Contra-indications”).
Cisapride
There have been reports of cardiac events including torsades de pointes in patients to whom fluconazole and cisapride were co-administered. In most of these cases, the patients appear to have been predisposed to arrhythmias or had serious underlying illnesses, and the relationship of the reported events to a possible fluconazole-cisapride drug interaction is unclear. Because of the potential seriousness of such an interaction, co-administration of cisapride is contra-indicated in patients receiving fluconazole. (See “Contra-indications”).
Zidovudine
Two kinetic studies resulted in increased levels of zidovudine most likely caused by the decreased conversion of zidovudine to its major metabolite. One study determined zidovudine levels in AIDS or ARC patients before and following fluconazole 200mg daily for 15 days. There was a significant increase in zidovudine AUC (20%). A second randomised, two-period, two- treatment cross-over study examined zidovudine levels in HIV infected patients. On two occasions, 21 days apart, patients received zidovudine 200mg every eight hours either with or without fluconazole 400mg daily for seven days. The AUC of zidovudine significantly increased (74%) during co- administration with fluconazole. Patients receiving this combination should be monitored for the development of zidovudine-related adverse reactions.
Rifabutin
There have been reports that an interaction exists when fluconazole is administered concomitantly with rifabutin, leading to increased serum levels of rifabutin. There have been reports of uveitis in patients to whom fluconazole and rifabutin were co-administered. Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored.
Tacrolimus
There have been reports that an interaction exists when fluconazole is administered concomitantly with tacrolimus, leading to increased serum levels of tacrolimus. There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were co-administered. Pateints receiving tacrolimus and fluconazole concomitantly should be carefully monitored.
The use of fluconazole in patients concurrently taking astemizole or other drugs metabolised by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. In the absence of definitive information, caution should be used when co-administering fluconazole. Patients should be carefully monitored.
Interaction studies have shown that when oral fluconazole is co-administered with food, cimetidine, antacids or following total body irradiation for bone marrow transplantation, no clinically significant impairment of fluconazole absorption occurs.
Physicians should be aware that drug-drug interaction studies with other medications have not been conducted, but that such interactions may occur.
4.6 Pregnancy And Lactation
Use during pregnancy
There are no adequate and well controlled studies in pregnant women. There have been reports of multiple congenital abnormalities in infants whose mothers were being treated for 3 or more months with high dose (400-800 mg/day) fluconazole therapy for coccidioidomycosis. The relationship between fluconazole and these events is unclear.
Accordingly, fluconazole should not be used in pregnancy, or in women of childbearing potential unless adequate contraception is employed. Use in pregnancy should be avoided except in patients with severe or potentially life-threatening fungal infections in whom fluconazole may be used if the anticipated benefit outweighs the possible risk to the foetus.
Use during lactation
Fluconazole is found in human breast milk at concentrations similar to plasma, hence its use in nursing mothers is not recommended.
4.7 Effects On Ability To Drive And Use Machines
Experience with fluconazole indicates that therapy is unlikely to impair a patient's ability to drive or use machinery.
4.8 Undesirable Effects
The following treatment–related undesirable effects were reported in 4,048 patients receiving fluconazole for 7 or more days in clinical trials:
Organ systems
|
Very Common
>1/10
|
Common
>1/100,
<1/10
|
Uncommon
>1/1,000,
<1/100
|
Rare
>1/10,000,
<1/1,000
|
Very rare
<1/10,000
|
General
|
|
|
fatigue, malaise, asthenia, fever
|
|
|
Central and Peripheral Nervous System
|
|
Headache
|
Convulsions, dizziness, Paraesthesia, tremor,
vertigo
|
|
|
Skin and Appendages
|
|
Skin Rash
|
Pruritus
|
Exfoliative Skin disorder (Stevens- Johnson Syndrome)
|
|
Gastrointestinal
|
|
Nausea and Vomiting, abdominal pain, diarrhoea
|
Anorexia, constipation, dyspepsia, flatulence
|
|
|
Musculoskeletal
|
|
|
Myalgia
|
|
|
Autonomic Nervous System
|
|
|
Dry mouth, increased sweating
|
|
|
Psychiatric
|
|
|
Insomnia, somnolence
|
|
|
Liver and Biliary System
|
|
Clinically significant increase of AST, ALT and alkaline phosphatase
|
Cholestasis, hepatocellular damage, jaundice. Clinically significant increase o total bilirubin
|
Hepatic Necrosis
|
|
Special Senses
|
|
|
Taste perversion
|
|
|
Hematopoietic and Lymphatic
|
|
|
Anaemia
|
|
|
Immunologic
|
|
|
|
Anaphylaxis
|
|
Adverse clinical events were reported more frequently in HIV infected patients (21%) than in non-HIV infected patients (13%). However, the patterns of adverse events in HIV infected and non-HIV infected patients were similar.
In addition, the following adverse events have occurred under conditions where a causal association is uncertain (e.g. open trials, during post-marketing experience):
Organ Systems
|
Very Common
>1/10
|
Common
> 1/100,
< 1/10
|
Uncommon
> 1/1,000,
< 1/1,00
|
Rare
> 1/10,000,
< 1/1,000
|
Very rare
< 1/10,000
|
Central and Peripheral Nervous System
|
|
|
|
Seizures
|
|
Skin and Appendages
|
|
|
|
Alopecia
|
Exfoliative skin disorder (Stevens-Johnson Syndrome and toxic epidermal necrolysis), erythema exudativum multiforme
|
Liver and Biliary system
|
|
|
|
Hepatic Failure,hepatitis, hepatic necrosis
|
|
Immunologic
|
|
|
|
|
Anaphylaxis, angiodema, face oedema and pruritus
|
Hematopoietic and Lymphatic
|
|
|
|
Leukopenia, including neutropenia and agranulocytosis, thrombocytopenia
|
|
Metabolic
|
|
|
|
Hypercholesterolaemia, hypertriglyceridaemia, hypokalaemia
|
|
4.9 Overdose
There have been reports of overdosage with fluconazole and in one case, a 42 year-old patient infected with human immunodeficiency virus developed hallucinations and exhibited paranoid behaviour after reportedly ingesting 8200mg of fluconazole, unverified by his physician. The patient was admitted to the hospital and his condition resolved within 48 hours.
In the event of overdosage, supportive measures and symptomatic treatment, with gastric lavage if necessary, may be adequate.
As fluconazole is largely excreted in the urine, forced volume diuresis would probably increase the elimination rate. A three hour haemodialysis session decreases plasma levels by approximately 50%.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
J02A C01 Antimycotics for systemic use – triazole derivatives Fluconazole, a member of the triazole class of antifungal agents, is a potent and selective inhibitor of fungal enzymes necessary for the synthesis of ergosterol.
Fluconazole shows little pharmacological activity in a wide range of animal studies. Some prolongation of pentobarbital sleeping times in mice (p.o.), increased mean arterial and left ventricular blood pressure and increased heart rate in anaesthetised cats (i.v.) occurred. Inhibition of rat ovarian aromatase was observed at high concentrations.
There have been reports of cases of superinfection with Candida species other than C. albicans, which are often inherently not susceptible to fluconazole (e.g. Candida krusei). Such cases may require alternative antifungal therapy.
Fluconazole is highly specific for fungal cytochrome P-450 dependent enzymes. Fluconazole 50mg daily given up to 28 days has been shown not to affect testosterone plasma concentrations in males or steroid concentrations in females of child-bearing age. Fluconazole 200-400mg daily has no clinically significant effect on endogenous steroid levels or on ACTH stimulated response in healthy male volunteers. Interaction studies with antipyrine indicate that single or multiple doses of fluconazole 50mg do not affect its metabolism.
5.2 Pharmacokinetic Properties
The pharmacokinetic properties of fluconazole are similar following administration by the intravenous or oral route. After oral administration fluconazole is well absorbed and plasma levels (and systemic bioavailability) are over 90% of the levels achieved after intravenous administration. Oral absorption is not affected by concomitant food intake. Peak plasma concentrations in the fasting state occur between 0.5 and 1.5 hours post-dose with a plasma elimination half-life of approximately 30 hours. Plasma concentrations are proportional to dose. Ninety percent steady-state levels are reached by day 4-5 with multiple once daily dosing.
Administration of a loading dose (on day 1) of twice the usual daily dose enables plasma levels to approximate to 90% steady-state levels by day 2. The apparent volume of distribution approximates to total body water. Plasma protein binding is low (11-12%).
Fluconazole achieves good penetration in all body fluids studied. The levels of fluconazole in saliva and sputum are similar to plasma levels. In patients with fungal meningitis, fluconazole levels in the CSF are approximately 80% of the corresponding plasma levels.
High skin concentrations of fluconazole, above serum concentrations, are achieved in the stratum corneum, epidermis-dermis and eccrine sweat. Fluconazole accumulates in the stratum corneum. At a dose of 50mg once daily, the concentration of fluconazole after 12 days was 73 microgram/g and 7 days after cessation of treatment the concentration was still 5.8 microgram/g.
The major route of excretion is renal, with approximately 80% of the administered dose appearing in the urine as unchanged drug. Fluconazole clearance is proportional to creatinine clearance. There is no evidence of circulating metabolites.
The long plasma elimination half-life provides the basis for single dose therapy for genital candidiasis and once daily dosing for other indications.
5.3 Preclinical Safety Data
Reproductive Toxicity increases in fetal anatomical variants (supernumary ribs, renal pelvis dilation) and delays in ossification were observed at 25 and
50mg/kg and higher doses. At doses ranging from 80mg/kg (approximately 20-60x the recommended human dose) to 320mg/kg embryolethality in rats was increased and fetal abnormalities included wavy ribs, cleft palate and abnormal cranio-facial ossification.
Carcinogenesis Fluconazole showed no evidence of carcinogenic potential in mice and rats treated orally for 24 months at doses of 2.5, 5 or 10mg/kg/day. Male rats treated with 5 and 10mg/kg/day had an increased incidence of hepatocellular adenomas.
Mutagenesis Fluconazole, with or without metabolic activation, was negative in tests for mutagenicity in 4 strains of S.typhimurium and in the mouse lymphoma L5178Y system. Cytogenetic studies in vivo (murine bone marrow cells, following oral administration of fluconazole) and in vitro (human lymphocytes exposed to fluconazole at 1000µg/ml) showed no evidence of chromosomal mutations.
Impairment of Fertility Fluconazole did not affect the fertility of male or female rats treated orally with daily doses of 5, 10 or 20mg/kg or with parenteral doses of 5, 25 or 75mg/kg, although the onset of parturition was slightly delayed at 20mg/kg p.o. In an intravenous perinatal study in rats at 5, 20 and 40mg/kg, dystocia and prolongation of parturition were observed in a few dams at 20mg/kg and 40mg/kg, but not at 5mg/kg. The disturbances in parturition were reflected by a slight increase in the number of still-born pups and decrease of neonatal survival at these dose levels. The effects on parturition in rats are consistent with the species specific oestrogen-lowering property produced by high doses of fluconazole. Such a hormone change has not been observed in women treated with fluconazole.
6. Pharmaceutical Particulars
6.1 List Of Excipients
Lactose
Pregelatinised Maize Starch
Sodium Laurilsulfate
Colloidal Anhydrous Silica
Magnesium Stearate
Purified Talc
Capsule shell:
Gelatin
Brilliant Blue E133
Erythrosin E127
Titanium Dioxide E171
Water
Sodium Laurilsulfate
6.2 Incompatibilities
No specific incompatibilities have been noted.
6.3 Shelf Life
2 years
6.4 Special Precautions For Storage
Do not store above 25°C.
6.5 Nature And Contents Of Container
Aluminium and PVC/PVdC blister.
Pack size: 7 capsules.
6.6 Special Precautions For Disposal And Other Handling
Not applicable.
Administrative Data
7. Marketing Authorisation Holder
FDC International Ltd
Unit 6 Fulcrum 1
Solent Way
Whiteley
Fareham
Hants
PO15 7FE
United Kingdom
8. Marketing Authorisation Number(S)
PL15872/0014
9. Date Of First Authorisation/Renewal Of The Authorisation
16 November 2006
10. Date Of Revision Of The Text
17 June 2009
